HU220041B - Fluor-alkoxi-helyettesített benzamidszármazékok, eljárás előállításukra és ezeket a vegyületeket tartalmazó gyógyászati készítmények - Google Patents
Fluor-alkoxi-helyettesített benzamidszármazékok, eljárás előállításukra és ezeket a vegyületeket tartalmazó gyógyászati készítmények Download PDFInfo
- Publication number
- HU220041B HU220041B HU9503541A HU9503541A HU220041B HU 220041 B HU220041 B HU 220041B HU 9503541 A HU9503541 A HU 9503541A HU 9503541 A HU9503541 A HU 9503541A HU 220041 B HU220041 B HU 220041B
- Authority
- HU
- Hungary
- Prior art keywords
- salts
- formula
- halogen
- hydrogen
- difluoromethoxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/56—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
Abstract
Description
Placebo+ | Placebo+ | 1. számú |
látszólagos | provokáció | vegyület+ |
provokáció | provokáció | |
N, védett 15 | 13 | 14 |
15 | 2 | 8 |
Medián 2,2 (1) | 9,8 (4,5) | 2,5(1,1) |
Min.-Max. 1,1-3,8 | 1,0-21,4 | 1,5-4,2 |
Neutrofil granulociták (x | 106/10 ml) | |
Medián 0,04 (1) | 0,44(11) | 0,0 (0) |
Min.-Max. 0,01-0,1 | 0,01-1,1 | 0,0-0,08 |
Medián 0,8 (1) | 5,8 (7,3) | 1,2 (1,5) |
Min.-Max. 0,4-1,8 | 0,3-14,5 | 0,6-2,5 |
Makrofágok (χ 106/10 ml) | ||
Medián 1,5 (1) | 3,2 (2,1) | 1,2 (0,8) |
Min.-Max. 0,8-2,3 | 0,7-6,2 | 0,9-2,3 |
Claims (13)
- SZABADALMI IGÉNYPONTOK1. (I) általános képletű vegyületek (mely képletbenR1 jelentése 3-7 szénatomos cikloalkoxi-, 3-7 szénatomos cikloalkil-metoxi vagy benzil-oxi-csoport, és R2 jelentése teljesen vagy részlegesen fluorhelyettesített 1 -4 szénatomos alkoxicsoport; vagy R1 jelentése teljesen vagy részlegesen fluorhelyettesített 1 -4 szénatomos alkoxicsoport; és R2 jelentése 3-7 szénatomos cikloalkil-metoxi- vagy benzil-oxi-csoport; ésR3 jelentése R34, R35, R36 és R37 által helyettesített piridilcsoport, ahol R34 jelentése halogénatom;R35 jelentése hidrogén- vagy halogénatom;R36 jelentése hidrogén- vagy halogénatom; és R37 jelentése hidrogén- vagy halogénatom) és e vegyületek sói, valamint a piridinek N-oxidjai és ezek sói.
- 2. Az 1. igénypont szerinti (I) általános képletű vegyületek, amelyekbenR1 jelentése 3-7 szénatomos cikloalkoxi-, 3-7 szénatomos cikloalkil-metoxi- vagy benzil-oxi-csoport;R2 jelentése teljesen vagy részlegesen fluorhelyettesített 1 -4 szénatomos alkoxicsoport, ésR3 jelentése R34, R35, R36 és R37 által helyettesített piridilcsoport, aholR34 jelentése halogénatom;R35 jelentése hidrogén- vagy halogénatom;R36 jelentése hidrogén- vagy halogénatom; és R37 jelentése hidrogén- vagy halogénatom, továbbá a fenti vegyületek sói, a piridinek N-oxidjai és ezek sói.
- 3. Az 1. igénypont szerinti (I) általános képletű vegyületek, amelyekbenR1 jelentése teljesen vagy részlegesen fluorhelyettesített 1 -4 szénatomos alkoxicsoport;R2 jelentése 3-7 szénatomos cikloalkil-metoxi- vagy benzil-oxi-csoport; ésR3 jelentése R34, R35, R36 és R37 által helyettesített piridilcsoport, ahol R34 jelentése halogénatom;R35 jelentése hidrogén- vagy halogénatom;R36 jelentése hidrogén- vagy halogénatom; és R37 jelentése hidrogén- vagy halogénatom, és e vegyületek sói, a piridinek N-oxidjai és ezek sói.
- 4. Az 1. igénypont szerinti (I) általános képletű vegyületek, amelyekbenR1 jelentése 3-5 szénatomos cikloalkoxi-, 3-5 szénatomos cikloalkil-metoxi- vagy benzil-oxi-csoport;R2 jelentése teljesen vagy részlegesen fluorhelyettesített 1 -4 szénatomos alkoxicsoport; ésR3 jelentése R34, R35, R36 és R37 által helyettesített piridilcsoport, ahol R34 jelentése halogénatom;R35 jelentése hidrogén- vagy halogénatom;R36 jelentése hidrogén- vagy halogénatom; és R37 jelentése hidrogén- vagy halogénatom, továbbá e vegyületek sói, a piridinek N-oxidjai és ezek sói.
- 5. Az 1. igénypont szerinti (I) általános képletű vegyületek, amelyekbenR1 jelentése teljesen vagy részlegesen fluorhelyettesített 1 -4 szénatomos alkoxicsoport;R2 jelentése 3-5 szénatomos cikloalkil-metoxi- vagy benzil-oxi-csoport, ésR3 jelentése R34, R35, R36 és R37 által helyettesített piridilcsoport, ahol R34 jelentése halogénatom;R35 jelentése hidrogén- vagy halogénatom;R36 jelentése hidrogén- vagy halogénatom; és R37 jelentése hidrogén- vagy halogénatom, továbbá e vegyületek sói, a piridinek N-oxidjai és ezek sói.
- 6. Az 1. igénypont szerinti (I) általános képletű vegyületek, amelyekbenR* jelentése 3-5 szénatomos cikloalkoxi-, 3-5 szénatomos cikloalkil-metoxi- vagy benzil-oxi-csoport;R2 jelentése teljesen vagy részlegesen fluorhelyettesített 1 -4 szénatomos alkoxicsoport, ésR3 jelentése 3,5-diklór-pirid-4-il-, 2-klór-pirid-3-il-,3,5-dibróm-pirid-2-il-, 2,3,5,6-tetrafluor-pirid-4il-, 3-klór-2,5,6-trifluor-pirid-4-il-, 3,5-diklór-2,68HU 220 041 Β difluor-pirid-4-il- vagy 2,6-diklór-pirid-3-il-csoport, továbbá e vegyületek sói, a piridinek N-oxidjai és ezek sói.
- 7. Az 1. igénypont szerinti (I) általános képletű vegyületek, amelyekbenR1 jelentése teljesen vagy részlegesen fluorhelyettesített 1 -4 szénatomos alkoxicsoport;R2 jelentése 3-5 szénatomos cikloalkil-metoxi- vagy benzil-oxi-csoport, ésR3 jelentése 3,5-diklór-pirid-4-il-, 2-klór-pirid-3-il-,3,5-dibróm-pirid-2-il-, 2,3,5,6-tetrafluor-pirid-4-il-,3-klór-2,5,6-trifluor-pirid-4-il-, 3,5-diklór-2,6-difluor-pirid-4-il- vagy 2,6-diklór-pirid-3-il-csoport, továbbá e vegyületek sói, a piridinek N-oxidjai és ezek sói.
- 8. Az 1. igénypont szerinti (I) általános képletű vegyületek, amelyekbenR1 jelentése difluor-metoxi-csoport;R2 jelentése ciklopropil-metoxi-csoport, ésR3 jelentése 3,5-diklór-pirid-4-il-, 2-klór-pirid-3-il-, 3,5dibróm-pirid-2-il-, 2,3,5,6-tetrafluor-pirid-4-il-, 3klór-2,5,6-trifluor-pirid-4-il-, 3,5-diklór-2,6-difluorpirid-4-il- vagy 2,6-diklór-pirid-3-il-csoport, továbbá e vegyületek sói, a piridinek N-oxidjai és ezek sói.
- 9. N-(3,5-Diklór-pirid-4-il)-3-(ciklopropil-metoxi)4-(difluor-metoxi)-benzamid, továbbá e vegyület sói, a piridin N-oxidja és ennek sói.
- 10. Eljárás az 1. igénypont szerinti (I) általános képletű vegyületek, sóik, a piridinek N-oxidjai és ezek sói előllítására, azzal jellemezve, hogy valamely (II) általános képletű vegyületet (mely képletben R1 és R2 jelentése az 1. igénypontban megadott és X jelentése megfelelő kilépőcsoport) valamely R3-NH2 általános képletű aminnal reagáltatunk (ahol R3 jelentése az 1. igénypontban megadott), majd kívánt esetben egy kapott (I) általános képletű vegyületet sójává alakítunk és/vagy kívánt esetben egy kapott piridint N-oxiddá alakítunk, és ezt a vegyületet kívánt esetben sójává alakítjuk, vagy kívánt esetben egy (I) általános képletű vegyület kapott sóját a szabad (I) általános képletű vegyületté alakítjuk.
- 11. A 10. igénypont szerinti eljárás N-(3,5-diklórpirid-4-il)-3-(ciklopropil-metoxi)-4-(difluor-metoxi)benzamid, továbbá e vegyület sói, a piridin N-oxidja és ennek sói előállítására, azzal jellemezve, hogy valamely (II) általános képletű vegyületet (mely képletben R1 jelentése difluor-metoxi-csoport, R2 jelentése ciklopropil-metoxi-csoport és X jelentése a 10. igénypontban megadott) valamely R3-NH2 általános képletű aminnal reagáltatunk (mely képletben R3 jelentése 3,5diklór-piridil-pirid-4-il-csoport), majd kívánt esetben a kapott (I) általános képletű vegyületet sójává alakítjuk és/vagy kívánt esetben a kapott piridint N-oxiddá alakítjuk és kívánt esetben ezt a vegyületet sójává alakítjuk, vagy kívánt esetben a kapott (I) általános képletű vegyület sójából az (I) általános képletű vegyületet felszabadítjuk.
- 12. Gyógyászati készítmény, amely egy vagy több, az 1. igénypont szerinti (I) általános képletű vegyületet és szokásos gyógyászati hordozóanyagokat és/vagy segédanyagokat tartalmaz.
- 13. A 12. igénypont szerinti gyógyászati készítmény, amely N-(3,5-diklór-pirid-4-il)-3-(ciklopropil-metoxi)4-(difluor-metoxi)-benzamidot, e vegyület sóját, a piridin N-oxidját vagy annak sóját tartalmazza.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH199693 | 1993-07-02 | ||
PCT/EP1994/002169 WO1995001338A1 (de) | 1993-07-02 | 1994-07-02 | Fluoralkoxy substituierte benzamide und ihre verwendung als zyklisch-nukleotid phosphodiesterase-inhibitoren |
Publications (3)
Publication Number | Publication Date |
---|---|
HU9503541D0 HU9503541D0 (en) | 1996-02-28 |
HUT73232A HUT73232A (en) | 1996-07-29 |
HU220041B true HU220041B (hu) | 2001-10-28 |
Family
ID=4223466
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU9503541A HU220041B (hu) | 1993-07-02 | 1994-07-02 | Fluor-alkoxi-helyettesített benzamidszármazékok, eljárás előállításukra és ezeket a vegyületeket tartalmazó gyógyászati készítmények |
Country Status (28)
Country | Link |
---|---|
US (1) | US5712298A (hu) |
EP (1) | EP0706513B1 (hu) |
JP (1) | JP3093271B2 (hu) |
KR (1) | KR100331255B1 (hu) |
CN (1) | CN1046939C (hu) |
AT (1) | ATE217612T1 (hu) |
AU (1) | AU687087B2 (hu) |
CA (1) | CA2165192C (hu) |
CY (2) | CY2389B1 (hu) |
CZ (1) | CZ290266B6 (hu) |
DE (2) | DE59410119D1 (hu) |
DK (1) | DK0706513T3 (hu) |
ES (1) | ES2176252T3 (hu) |
FI (1) | FI112864B (hu) |
FR (1) | FR10C0052I2 (hu) |
HK (1) | HK1011690A1 (hu) |
HU (1) | HU220041B (hu) |
LU (1) | LU91709I2 (hu) |
LV (1) | LV13074B (hu) |
NO (2) | NO305598B1 (hu) |
NZ (1) | NZ271316A (hu) |
PL (1) | PL178314B1 (hu) |
PT (1) | PT706513E (hu) |
RU (1) | RU2137754C1 (hu) |
SG (1) | SG143011A1 (hu) |
SI (1) | SI0706513T1 (hu) |
SK (1) | SK283263B6 (hu) |
WO (1) | WO1995001338A1 (hu) |
Families Citing this family (189)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5698711A (en) | 1991-01-28 | 1997-12-16 | Rhone-Poulenc Rorer Limited | Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group |
GB9311281D0 (en) * | 1993-06-01 | 1993-07-21 | Rhone Poulenc Rorer Ltd | Novel composition of matter |
US6096768A (en) * | 1992-01-28 | 2000-08-01 | Rhone-Poulenc Rorer Limited | Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group |
WO1997003967A1 (en) * | 1995-07-22 | 1997-02-06 | Rhone-Poulenc Rorer Limited | Substituted aromatic compounds and their pharmaceutical use |
DK0923568T5 (da) * | 1996-08-19 | 2003-11-03 | Altana Pharma Ag | Hidtil ukendte benzofuran-4-carboxamider |
US6331543B1 (en) | 1996-11-01 | 2001-12-18 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use |
US5958926A (en) * | 1996-11-01 | 1999-09-28 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses |
US5874437A (en) * | 1996-11-01 | 1999-02-23 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses |
USRE37234E1 (en) * | 1996-11-01 | 2001-06-19 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiestrase inhibitor compounds, compositions and their uses |
JP2001504457A (ja) * | 1996-11-01 | 2001-04-03 | ニトロメド インコーポレーテッド | ニトロソ化およびニトロシル化ホスホジエステラーゼ阻害剤化合物、組成物及びその使用法 |
DE69835594T2 (de) * | 1997-02-17 | 2007-08-16 | Altana Pharma Ag | Zusammensetzungen zur behandlung von irds oder ards die 3-(cyclopropylmethoxy)-n-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy) benzamid und lungensurfactant enthalten |
US6472425B1 (en) | 1997-10-31 | 2002-10-29 | Nitromed, Inc. | Methods for treating female sexual dysfunctions |
US6118017A (en) * | 1998-04-14 | 2000-09-12 | Smithkline Beecham Corporation | Substituted-(3-cyclopentyloxy-4-methoxyphenyl)-3-phenylcyanocyclobutan-1-one |
PT1161239E (pt) * | 1999-03-10 | 2005-02-28 | Altana Pharma Ag | 3-ciclopropilmetoxi-4-difluorometoxi-n-(3,5-dicloropirid-4-il)-benzamida para o tratamento da esclerose multipla |
US6653309B1 (en) | 1999-04-26 | 2003-11-25 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme technical field of the invention |
CA2372850C (en) | 1999-05-04 | 2011-01-18 | Ulrich Kilian | Synergistic combination comprising roflumilast and a pde-3 inhibitor |
JP5038568B2 (ja) | 1999-08-21 | 2012-10-03 | ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング | 協力剤の組合せ物 |
AU6196201A (en) * | 2000-05-25 | 2001-12-03 | Merck Frosst Canada Inc | Fluoroalkoxy-substituted benzamide dichloropyridinyl n-oxide pde4 inhibitor |
DE10043074A1 (de) | 2000-09-01 | 2002-03-14 | Aventis Cropscience Gmbh | Herbizid wirksame Benzoylcyclohexandione |
EP1188438A1 (en) * | 2000-09-15 | 2002-03-20 | Warner-Lambert Company | Pharmaceutical composition for preventing or treating a disease associated with an excess of Il-12 production |
EP1199074A1 (en) * | 2000-09-15 | 2002-04-24 | Warner-Lambert Company | Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production |
WO2002038155A1 (en) * | 2000-11-07 | 2002-05-16 | Merck & Co., Inc. | Method of treatment with a combination of a pde4 inhibitor and a leukotriene antagonist |
US20100310477A1 (en) * | 2000-11-28 | 2010-12-09 | Boehringer Ingelheim Pharma Gmbh & Co. Kg. | Pharmaceutical compositions based on anticholingerics and additional active ingredients |
US6699890B2 (en) | 2000-12-22 | 2004-03-02 | Memory Pharmaceuticals Corp. | Phosphodiesterase 4 inhibitors |
US7205320B2 (en) | 2001-01-22 | 2007-04-17 | Memory Pharmaceuticals Corp. | Phosphodiesterase 4 inhibitors |
US7153871B2 (en) | 2001-01-22 | 2006-12-26 | Memory Pharmaceuticals Corporation | Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs |
US6872382B1 (en) | 2001-05-21 | 2005-03-29 | Alcon, Inc. | Use of selective PDE IV inhibitors to treat dry eye disorders |
AU2002257459B2 (en) | 2001-05-24 | 2006-12-14 | Merck Frosst Canada Ltd | 1-biaryl-1,8-napthyridin-4-one phosphodiesterase-4 inhibitors |
MXPA04001253A (es) * | 2001-08-09 | 2004-06-03 | Ono Pharmaceutical Co | Derivados de acidos carboxilicos y agente farmaceutico que comprende los mismos como ingrediente activo. |
MY140561A (en) * | 2002-02-20 | 2009-12-31 | Nycomed Gmbh | Dosage form containing pde 4 inhibitor as active ingredient |
DE10207160A1 (de) * | 2002-02-20 | 2003-12-18 | Altana Pharma Ag | Darreichungsform enthaltend PDE 4-Hemmer als Wirkstoff |
TWI347845B (en) * | 2002-03-06 | 2011-09-01 | Nycomed Gmbh | Pharmaceutical compositions,combinations,and kits for the treatment of respiratory diseases and use of the same |
WO2003094967A2 (en) * | 2002-05-07 | 2003-11-20 | Altana Pharma Ag | New combination of reversible proton pump inhibitors and airway therapeutics for treating airway disorders |
WO2003094968A2 (en) * | 2002-05-07 | 2003-11-20 | Altana Pharma Ag | Combination of a proton pump inhibitor and a respiratory agent for the treatment of respiratory diseases |
EP1505972A2 (en) * | 2002-05-16 | 2005-02-16 | Pharmacia Corporation | A selective inos inhibitor and a pde inhibitor in combination for the treatment of respiratory diseases |
EP1511516B1 (en) * | 2002-05-28 | 2008-12-17 | Nycomed GmbH | Topically applicable pharmaceutical preparation |
EP1539697A1 (en) | 2002-07-19 | 2005-06-15 | Memory Pharmaceutical Corporation | Phosphodiesterase 4 inhibitors, including n-substituted aniline and diphenylamine analogs |
BR0313000A (pt) | 2002-07-19 | 2005-07-12 | Memory Pharm Corp | Compostos, composição farmacêutica e método para efetuar a inibição da enzima pde4, realçar a cognição e/ou tratar a psicose em um paciente |
WO2004022536A1 (en) * | 2002-09-04 | 2004-03-18 | Glenmark Pharmaceuticals Limited | New heterocyclic amide compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them |
EP1536794A2 (en) * | 2002-09-06 | 2005-06-08 | Merck & Co., Inc. | Treatment of rheumatoid arthritis by inhibition of pde4 |
WO2004026406A1 (en) | 2002-09-20 | 2004-04-01 | Alcon, Inc. | Use of cytokine synthesis inhibitors for the treatment of dry eye disorders |
US6822114B1 (en) | 2002-10-08 | 2004-11-23 | Albemarle Corporation | Process for production of fluoroalkoxy-substituted benzamides and their intermediates |
BR0314721A (pt) | 2002-10-23 | 2005-08-02 | Glenmark Pharmaceuticals Ltd | Compostos tricìclicos úteis para tratamento de distúrbios inflamatórios e alérgicos, processo para sua preparação e composições farmacêuticas contendo-os |
NZ540138A (en) * | 2002-11-19 | 2008-07-31 | Memory Pharm Corp | Pyridine n-oxide compounds as phosphodiesterase 4 inhibitors |
WO2004047829A1 (en) * | 2002-11-27 | 2004-06-10 | Altana Pharma Ag | New synergistic combination comprising roflumilast and formoterol |
US20060083714A1 (en) * | 2003-01-27 | 2006-04-20 | Warner James M | Combination of a pde iv inhibitor and a tnf-alpha antagonist |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
EA009985B1 (ru) | 2003-03-10 | 2008-04-28 | Никомед Гмбх | Новый способ получения рофлумиласта |
BRPI0409229A (pt) | 2003-04-01 | 2006-03-28 | Applied Research Systems | inibidores das fosfodiesterases na infertilidade |
DE602004020332D1 (de) | 2003-04-11 | 2009-05-14 | Glenmark Pharmaceuticals Sa | Neue heterozyklische verbindungen, die sich für die behandlung von entzündlichen und allergischen erkrankungen eignen: verfahren zu deren herstellung und pharmazeutische zusammensetzungen, die diese enthalten |
DE10318610A1 (de) * | 2003-04-24 | 2004-11-11 | Elbion Ag | 7-Azaindole und deren Verwendung als Therapeutika |
WO2004098595A1 (en) * | 2003-05-12 | 2004-11-18 | Altana Pharma Ag | COMPOSITION COMPRISING ROFLUMILAST AND A TNFα ANTAGONIST |
WO2004098597A1 (en) * | 2003-05-12 | 2004-11-18 | Altana Pharma Ag | Composition comprising roflumilast and shuil-1r ii |
WO2004098596A1 (en) * | 2003-05-12 | 2004-11-18 | Altana Pharma Ag | Composition comprising roflumilast and il-1 trap |
WO2004098598A1 (en) * | 2003-05-12 | 2004-11-18 | Altana Pharma Ag | COMPOSITION COMPRISING ROFLUMILAST AND A TNFα ANTAGONIST |
WO2004103407A2 (en) | 2003-05-22 | 2004-12-02 | Altana Pharma Ag | Composition comprising a pde4 inhibitor and a pde5 inhibitor |
GEP20084406B (en) * | 2003-05-30 | 2008-06-25 | Ranbaxy Lab Ltd | Substituted pyrrole derivatives and their use as hmg-co inhibitors |
US20050085430A1 (en) * | 2003-07-31 | 2005-04-21 | Robinson Cynthia B. | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease |
US20050026883A1 (en) * | 2003-07-31 | 2005-02-03 | Robinson Cynthia B. | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease |
US20090274676A1 (en) * | 2003-07-31 | 2009-11-05 | Robinson Cynthia B | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a pde-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease |
CA2537185A1 (en) * | 2003-08-29 | 2005-03-10 | Ranbaxy Laboratories Limited | Inhibitors of phosphodiesterase type-iv |
JP2007504201A (ja) * | 2003-09-05 | 2007-03-01 | アルタナ ファルマ アクチエンゲゼルシャフト | 真性糖尿病の治療のためのpde4阻害剤の使用 |
EP1670742A1 (en) * | 2003-09-12 | 2006-06-21 | Ranbaxy Laboratories Limited | Process for the preparation of roflumilast |
WO2005046676A1 (en) * | 2003-11-12 | 2005-05-26 | University Of South Carolina | Treatment or prevention of cardiovascular and respiratory disorders with novel substituted cyclic amp-specific phosphodiesterase inhibitors |
US20070167450A1 (en) * | 2003-11-20 | 2007-07-19 | Astellas Pharma Inc. | Agent for treating chronic pelvic pain syndrome |
EP1694655A2 (en) * | 2003-11-26 | 2006-08-30 | Ranbaxy Laboratories Limited | Phosphodiesterase inhibitors |
MY141255A (en) * | 2003-12-11 | 2010-03-31 | Memory Pharm Corp | Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs |
CN100512813C (zh) * | 2004-02-06 | 2009-07-15 | Meda制药有限及两合公司 | 用于呼吸道疾病治疗的抗胆碱能药和4型磷酸二酯酶抑制剂的组合 |
PT1713473E (pt) * | 2004-02-06 | 2013-05-13 | Meda Pharma Gmbh & Co Kg | Combinação de anticolinérgicos e glucocorticóides para o tratamento a longo prazo de asma e copd |
WO2005077906A1 (en) | 2004-02-18 | 2005-08-25 | Altana Pharma Ag | Novel guanidinyl-substituted hydroxy-6-phenylphenenthridines as effective phosphodiesterase (pde) 4 inhibitors |
JP2007524699A (ja) * | 2004-02-27 | 2007-08-30 | アルタナ ファルマ アクチエンゲゼルシャフト | ロフルミラストとグリコピロニウムとの組合せ物 |
PL2589599T4 (pl) | 2004-03-03 | 2015-06-30 | Takeda Gmbh | Nowe hydroksy-6-heteroarylofenantrydyny i ich zastosowanie jako inhibitorów PDE4 |
EP1775283A4 (en) * | 2004-07-14 | 2008-12-10 | Japan Tobacco Inc | 3-AMINOBENZAMIDE COMPOUND AND INHIBITORS OF THE ACTIVITY OF VANILLOID RECEPTOR 1 (VR1) |
BRPI0513286A (pt) | 2004-07-15 | 2008-05-06 | Japan Tobacco Inc | compostos de benzamida condensada e inibidores de atividade de receptor vanilóide subtipo (vr1), suas composições farmacêuticas, pacote comercial, fármaco e respectivos usos |
US20080009535A1 (en) * | 2004-08-30 | 2008-01-10 | Sarala Balachandran | Inhibitors of phosphodiesterase type-IV |
DE102004046235A1 (de) | 2004-09-22 | 2006-03-30 | Altana Pharma Ag | Arzneimittelzubereitung |
DE102004046236A1 (de) * | 2004-09-22 | 2006-03-30 | Altana Pharma Ag | Arzneimittelzubereitung |
JPWO2006041121A1 (ja) * | 2004-10-13 | 2008-05-15 | 協和醗酵工業株式会社 | 慢性皮膚疾患の治療および/または予防剤 |
EP1799632A2 (en) | 2004-10-13 | 2007-06-27 | Glenmark Pharmaceuticals S.A. | Process for the preparation of n-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-methanesulfonamido-dibenzo[b,d]furan-1-carboxamide |
JPWO2006041120A1 (ja) * | 2004-10-13 | 2008-05-15 | 協和醗酵工業株式会社 | 医薬組成物 |
SI1831227T1 (sl) | 2004-12-17 | 2013-09-30 | Glenmark Pharmaceuticals S.A. | Nove heterociklične spojine uporabne za zdravljenje vnetnih in alergijskih motenj |
MX2007007345A (es) | 2004-12-17 | 2007-09-07 | Glenmark Pharmaceuticals Sa | Compuestos heterociclicos novedosos utiles para el tratamiento de trastornos inflamatorios y alergicos. |
WO2006094640A2 (en) * | 2005-03-04 | 2006-09-14 | F.Hoffmann-La Roche Ag | Roflumilast and integrin inhibitor combination and method of treatment |
US8017633B2 (en) | 2005-03-08 | 2011-09-13 | Nycomed Gmbh | Roflumilast for the treatment of diabetes mellitus |
WO2006094942A1 (en) * | 2005-03-08 | 2006-09-14 | Nycomed Gmbh | Roflumilast for the treatment of diabetes mellitus |
SI1863476T1 (sl) * | 2005-03-16 | 2016-05-31 | Meda Pharma Gmbh & Co. Kg | Kombinacija antiholinergikov in antagonistov receptorja levkotriena za zdravljenje respiratornih bolezni |
CA2601250C (en) | 2005-03-16 | 2014-10-28 | Nycomed Gmbh | Taste masked dosage form containing roflumilast |
ES2433661T3 (es) | 2005-04-19 | 2013-12-12 | Takeda Gmbh | Roflumilast para el tratamiento de hipertensión pulmonar |
CN101171005A (zh) * | 2005-05-11 | 2008-04-30 | 尼科梅德有限责任公司 | Pde4抑制剂罗氟司特与四氢生物蝶呤衍生物的组合 |
CA2610881A1 (en) * | 2005-06-09 | 2006-12-14 | Santen Pharmaceutical Co., Ltd. | Eye drop containing roflumilast |
EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
JP2009506069A (ja) | 2005-08-26 | 2009-02-12 | ブレインセルス,インコーポレイティド | ムスカリン性受容体調節による神経発生 |
AU2006304787A1 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by PDE inhibition |
CA2625210A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
AU2006313430B2 (en) * | 2005-11-08 | 2012-09-06 | Ranbaxy Laboratories Limited | Process for (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt |
ES2389231T3 (es) | 2005-12-21 | 2012-10-24 | Meda Pharma Gmbh & Co. Kg | Combinación de anticolinérgicos, glucocorticoides y agonistas de beta2 para el tratamiento de enfermedades inflamatorias |
US7906508B2 (en) | 2005-12-28 | 2011-03-15 | Japan Tobacco Inc. | 3,4-dihydrobenzoxazine compounds and inhibitors of vanilloid receptor subtype 1 (VRI) activity |
US7863446B2 (en) * | 2006-01-19 | 2011-01-04 | Orchid Research Laboratories Limited | Heterocycles |
US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
AU2007223036A1 (en) * | 2006-03-08 | 2007-09-13 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
WO2008020314A2 (en) * | 2006-03-14 | 2008-02-21 | Ranbaxy Laboratories Limited | Statin stabilizing dosage formulations |
EP2377531A2 (en) | 2006-05-09 | 2011-10-19 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
US20100009983A1 (en) * | 2006-05-09 | 2010-01-14 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
EP2026813A2 (en) * | 2006-05-09 | 2009-02-25 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
EA032476B1 (ru) | 2006-07-05 | 2019-06-28 | Астразенека Аб | ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СПОСОБ ЕЁ ПОЛУЧЕНИЯ И ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ ИНГИБИТОРЫ HMG-CoA-РЕДУКТАЗЫ И ФОСФОДИЭСТЕРАЗЫ 4, ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЙ ЛЕГКИХ |
AU2007274724B2 (en) * | 2006-07-14 | 2012-07-26 | Ranbaxy Laboratories Limited | Polymorphic forms of an HMG-CoA reductase inhibitor and uses thereof |
CA2661850A1 (en) | 2006-09-01 | 2008-03-06 | Kyorin Pharmaceutical Co., Ltd. | Pyrazolopyridine carboxamide derivative and phosphodiesterase (pde) inhibitor containing the same |
US7998971B2 (en) * | 2006-09-08 | 2011-08-16 | Braincells Inc. | Combinations containing a 4-acylaminopyridine derivative |
US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
EP2066355A2 (en) * | 2006-09-19 | 2009-06-10 | Braincells, Inc. | Combination comprising a peroxisome proliferator activated receptor agent and a second neurogenic agent for treating a nervous system disorder, increasing neurodifferentiation and increasing neurogenesis |
US20100029728A1 (en) * | 2006-09-22 | 2010-02-04 | Ranbaxy Laboratories Limited | Phosphodiesterase inhibitors |
US20080221103A1 (en) * | 2007-03-09 | 2008-09-11 | Orchid Research Laboratories Ltd. | New heterocyclic compounds |
KR100844125B1 (ko) * | 2007-03-23 | 2008-07-04 | 한국화학연구원 | 7-(3′,4′-디알콕시페닐)-[1,2,4]트리아졸로[1,5-a]피리미딘 화합물, 이의 제조방법 및 이를 포함하는 천식 및만성폐쇄성 폐질환을 포함한 염증관련 질환, 관절염,아토피 피부염, 암 및 뇌질환의 치료 및 예방을 위한약제학적 조성물 |
ES2374337T3 (es) | 2007-05-16 | 2012-02-15 | Nycomed Gmbh | Derivados de pirazolona como inhibidores de pde4. |
US7879802B2 (en) | 2007-06-04 | 2011-02-01 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
CA2711865A1 (en) | 2008-01-11 | 2009-07-16 | Astellas Pharma Inc. | A pathological animal model simultaneously developing testicular pain or discomfort behaviors and urinary frequency |
JP5704924B2 (ja) | 2008-02-01 | 2015-04-22 | オーキッド リサーチ ラボラトリーズ リミティド | 新規複素環化合物 |
EP3239170B1 (en) | 2008-06-04 | 2019-03-20 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
US20100029689A1 (en) * | 2008-07-02 | 2010-02-04 | Memory Pharmaceuticals Corporation | Phosphodiesterase 4 inhibitors |
EP3241839B1 (en) | 2008-07-16 | 2019-09-04 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
EP2216327A1 (en) * | 2009-02-06 | 2010-08-11 | CHIESI FARMACEUTICI S.p.A. | Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors |
US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
US8367829B2 (en) | 2010-05-10 | 2013-02-05 | Gilead Sciences, Inc. | Bi-functional pyrazolopyridine compounds |
AR081026A1 (es) | 2010-05-10 | 2012-05-30 | Gilead Sciences Inc | Analogos de quinolina y su uso en el tratamiento de enfermedades respiratorias |
PT2585469T (pt) | 2010-06-24 | 2016-08-29 | Leo Pharma As | Compostos heterocíclicos de benzodioxolo ou benzodioxepina como inibidores da fosfodiesterase |
CN102311382B (zh) * | 2010-06-29 | 2014-05-21 | 大道隆达(北京)医药科技发展有限公司 | 罗氟司特的晶态及其制备方法 |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
CN102093194B (zh) * | 2010-12-24 | 2014-01-08 | 江苏先声药物研究有限公司 | 3-环丙基甲氧基-4-二氟甲氧基苯甲酸的合成方法 |
CN102617457A (zh) * | 2011-01-28 | 2012-08-01 | 天津药物研究院 | 一种制备罗氟司特的新方法 |
CN108676076A (zh) | 2011-03-01 | 2018-10-19 | 辛纳吉制药公司 | 制备鸟苷酸环化酶c激动剂的方法 |
CN102690194B (zh) * | 2011-03-24 | 2014-06-25 | 上海通远生物科技有限公司 | 3-环丙基甲氧基-4-二氟甲氧基苯甲酸的制备方法 |
CN102775345A (zh) * | 2011-05-13 | 2012-11-14 | 上海特化医药科技有限公司 | 制备罗氟司特的方法及中间体 |
CN102276522B (zh) * | 2011-06-15 | 2013-04-17 | 无锡泓兴生物医药科技有限公司 | 一种制备罗氟司特的方法及其中间体 |
CN102336703B (zh) * | 2011-07-20 | 2013-09-25 | 华润赛科药业有限责任公司 | 一种制备罗氟司特的方法 |
CN102351787B (zh) * | 2011-08-18 | 2014-08-13 | 天津市汉康医药生物技术有限公司 | 高生物利用度的罗氟司特化合物 |
WO2013030789A1 (en) | 2011-08-30 | 2013-03-07 | Ranbaxy Laboratories Limited | Pharmaceutical oral solid dosage form containing a poorly water soluble pde - iv inhibitor |
CN102336704B (zh) * | 2011-10-19 | 2013-04-17 | 丁克 | 一种制备罗氟司特的方法 |
BR112014009471A2 (pt) * | 2011-10-21 | 2017-04-18 | Chiesi Farm Spa | compostos, combinação de um composto, composição farmacêutica, uso de um composto, dispositivo e kit |
CN102336705B (zh) * | 2011-10-28 | 2013-03-27 | 成都苑东药业有限公司 | 一种制备n-(3,5-二氯吡啶-4-基)-3-环丙基甲氧基-4-二氟甲氧基苯甲酰胺的方法 |
CN104080770A (zh) * | 2011-11-09 | 2014-10-01 | 迈兰实验室有限公司 | 用于制备罗氟司特的改进方法 |
WO2013081565A1 (en) | 2011-11-21 | 2013-06-06 | Mahmut Bilgic | Pharmaceutical compositions comprising roflumilast and terbutaline |
WO2013077830A1 (en) | 2011-11-25 | 2013-05-30 | Mahmut Bilgic | Synergistilly active combinations of roflumilast and carmoterol |
WO2013084182A1 (en) | 2011-12-08 | 2013-06-13 | Glenmark Pharmaceuticals S.A. | Pharmaceutical composition that includes a pde4 enzyme inhibitor and an analgesic agent |
CN102603623A (zh) * | 2011-12-26 | 2012-07-25 | 北京赛林泰医药技术有限公司 | 制备高纯度罗氟司特的方法 |
EP2804603A1 (en) | 2012-01-10 | 2014-11-26 | President and Fellows of Harvard College | Beta-cell replication promoting compounds and methods of their use |
WO2013131255A1 (en) | 2012-03-07 | 2013-09-12 | Scinopharm (Changshu) Pharmaceutical, Ltd. | Preparation method of roflumilast |
WO2014012954A1 (en) | 2012-07-18 | 2014-01-23 | Takeda Gmbh | Treatment of partly controlled or uncontrolled severe asthma |
CN103630613B (zh) * | 2012-08-21 | 2015-08-05 | 北大方正集团有限公司 | 分离并检测罗氟司特及其中间体的方法 |
ES2625417T3 (es) * | 2012-10-17 | 2017-07-19 | Interquim, S.A. | Procedimiento para preparar roflumilast |
JP6426624B2 (ja) * | 2013-01-28 | 2018-11-21 | インコゼン・セラピューティクス・プライベート・リミテッド | ロフルミラストn−酸化物の吸入によって自己免疫、呼吸器性および炎症性の障害を処置する方法 |
WO2014117947A1 (en) | 2013-02-04 | 2014-08-07 | Grünenthal GmbH | 4-amino substituted condensed pyrimidine compounds as pde4 inhibitors |
BR112015018355A8 (pt) | 2013-02-04 | 2018-01-23 | Gruenenthal Gmbh | novos compostos de pirimidina condensados substituídos |
US9545446B2 (en) | 2013-02-25 | 2017-01-17 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase and their uses |
CA2905435A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
US9708367B2 (en) | 2013-03-15 | 2017-07-18 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase and their uses |
TW201512189A (zh) | 2013-04-16 | 2015-04-01 | Gruenenthal Chemie | 新型被取代之嘧啶縮合化合物 |
JP6606491B2 (ja) | 2013-06-05 | 2019-11-13 | シナジー ファーマシューティカルズ インコーポレイテッド | グアニル酸シクラーゼcの超高純度アゴニスト、その作成および使用方法 |
CN103304475A (zh) * | 2013-06-13 | 2013-09-18 | 湖南千金湘江药业股份有限公司 | 苯甲酰胺化合物及其制备方法和用途 |
IL280864B2 (en) | 2013-08-09 | 2024-03-01 | Ardelyx Inc | Compounds and methods for inhibiting phosphate transport |
PL3030565T3 (pl) | 2013-08-09 | 2017-12-29 | Grünenthal GmbH | Nowe podstawione skondensowane związki pirymidynowe |
AU2014307803A1 (en) | 2013-08-16 | 2016-03-10 | Universiteit Maastricht | Treatment of cognitive impairment with PDE4 inhibitor |
WO2015063669A1 (en) | 2013-10-30 | 2015-05-07 | Wockhardt Limited | Pharmaceutical compositions comprising combination of roflumilast and acebrophylline or pharmaceutically acceptable salts thereof |
WO2015173701A2 (en) | 2014-05-12 | 2015-11-19 | Glaxosmithkline Intellectual Property (No. 2) Limited | Pharmaceutical compositions for treating infectious diseases |
AR101196A1 (es) | 2014-07-16 | 2016-11-30 | Gruenenthal Gmbh | Compuestos de pirimidina sustituidos |
AR101198A1 (es) | 2014-07-16 | 2016-11-30 | Gruenenthal Gmbh | Pirimidinas 2,5-sustituidas como inhibidores de pde4b |
AR101197A1 (es) | 2014-07-16 | 2016-11-30 | Gruenenthal Gmbh | Pirimidinas 2,5-sustituidas |
CN104130116B (zh) * | 2014-08-18 | 2015-11-11 | 朱丽平 | 一种制备罗氟司特中间体的方法 |
KR101878621B1 (ko) | 2014-10-24 | 2018-07-13 | 히사미쓰 세이야꾸 가부시키가이샤 | 프로드러그 |
CN104447245B (zh) * | 2014-10-29 | 2017-06-06 | 成都森科制药有限公司 | 罗氟司特中间体、中间体制备方法及罗氟司特的制备方法 |
KR20170034707A (ko) | 2015-09-21 | 2017-03-29 | 한미약품 주식회사 | 로플루밀라스트 함유 경구용 고형제제 및 그 제조방법 |
EP3165224A1 (en) | 2015-11-09 | 2017-05-10 | Albert-Ludwigs-Universität Freiburg | Use of pde4 inhibitors for the prophylaxis and/or therapy of dyslipoproteinaemia and related disorders |
WO2017089347A1 (en) | 2015-11-25 | 2017-06-01 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas |
CN105523954B (zh) * | 2016-02-05 | 2017-07-18 | 徐江平 | 3‑环丙甲氧基‑4‑烷氧基苯甲酰胺类磷酸二酯酶4抑制剂 |
US9895359B1 (en) | 2017-06-07 | 2018-02-20 | Arcutis, Inc. | Inhibition of crystal growth of roflumilast |
US11129818B2 (en) | 2017-06-07 | 2021-09-28 | Arcutis Biotherapeutics, Inc. | Topical roflumilast formulation having improved delivery and plasma half life |
US11534493B2 (en) | 2017-09-22 | 2022-12-27 | Arcutis Biotherapeutics, Inc. | Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents |
AU2018357775B2 (en) | 2017-10-23 | 2024-02-15 | Boehringer Ingelheim International Gmbh | New combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (PF-ILD) |
AU2019281888B2 (en) | 2018-06-04 | 2024-05-02 | Arcutis Biotherapeutics Inc | Method and formulation for improving roflumilast skin penetration lag time |
WO2020237096A1 (en) | 2019-05-21 | 2020-11-26 | Ardelyx, Inc. | Combination for lowering serum phosphate in a patient |
IL295172A (en) | 2020-01-31 | 2022-09-01 | Arcutis Biotherapeutics Inc | Composition of topical roflumilest with improved administration and half-life in plasma |
US20230338345A1 (en) | 2020-04-23 | 2023-10-26 | Natural Medicine Institute Of Zhejiang Yangshengtang Co., Ltd. | Drug combination and use thereof |
CN111777550A (zh) * | 2020-06-01 | 2020-10-16 | 山东希尔康泰药业有限公司 | 罗氟司特结晶性粉末原料药生产制备方法 |
EP4255393A1 (en) | 2020-12-04 | 2023-10-11 | Arcutis Biotherapeutics, Inc. | Topical roflumilast formulation having antifungal properties |
CN116963773A (zh) * | 2021-01-21 | 2023-10-27 | 浙江养生堂天然药物研究所有限公司 | ***的组合物及方法 |
WO2022169615A1 (en) | 2021-02-05 | 2022-08-11 | Arcutis Biotherapeutics, Inc. | Roflumilast formulations with an improved pharmacokinetic profile |
US20230201177A1 (en) | 2021-12-28 | 2023-06-29 | Arcutis Biotherapeutics, Inc. | Topical Roflumilast Aerosol Foams |
WO2023129892A1 (en) | 2021-12-28 | 2023-07-06 | Arcutis Biotherapeutics, Inc. | Topical aerosol foams |
US20240108609A1 (en) | 2022-09-15 | 2024-04-04 | Arcutis Biotherapeutics, Inc. | Pharmaceutical compositions of roflumilast and solvents capable of dissolving high amounts of the drug |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3308239A1 (de) * | 1983-03-09 | 1984-09-13 | Basf Ag, 6700 Ludwigshafen | N-acyl-anthranilsaeurederivate, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung unerwuenschten pflanzenwuchses |
DK159431C (da) * | 1984-05-10 | 1991-03-18 | Byk Gulden Lomberg Chem Fab | 6-phenyl-3(2h)-pyridazinoner, fremgangsmaade til fremstilling deraf, laegemidler indeholdende disse samt anvendelse af forbindelserne til fremstilling af laegemidler |
JPS62158253A (ja) * | 1985-12-28 | 1987-07-14 | Kirin Brewery Co Ltd | 4−アミノピリジンアミド誘導体 |
IE71647B1 (en) * | 1991-01-28 | 1997-02-26 | Rhone Poulenc Rorer Ltd | Benzamide derivatives |
WO1992019602A1 (de) * | 1991-04-26 | 1992-11-12 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Neue pyridazine |
GB9212693D0 (en) * | 1992-06-15 | 1992-07-29 | Celltech Ltd | Chemical compounds |
DK0607373T3 (da) * | 1992-06-15 | 1997-10-13 | Celltech Therapeutics Ltd | Trisubstituerede phenylderivater som selektive phosphodiesterase IV-inhibitorer. |
CA2140441C (en) * | 1992-07-28 | 2006-11-21 | Garry Fenton | Inhibitors of c-amp phosphodiesterase and tnf |
-
1994
- 1994-07-02 CZ CZ19961A patent/CZ290266B6/cs not_active IP Right Cessation
- 1994-07-02 AU AU74907/94A patent/AU687087B2/en not_active Expired
- 1994-07-02 DE DE59410119T patent/DE59410119D1/de not_active Expired - Lifetime
- 1994-07-02 RU RU96102569A patent/RU2137754C1/ru active Protection Beyond IP Right Term
- 1994-07-02 EP EP94924713A patent/EP0706513B1/de not_active Expired - Lifetime
- 1994-07-02 KR KR1019950705937A patent/KR100331255B1/ko not_active IP Right Cessation
- 1994-07-02 SI SI9430420T patent/SI0706513T1/xx unknown
- 1994-07-02 DE DE122010000043C patent/DE122010000043I1/de active Pending
- 1994-07-02 PL PL94311820A patent/PL178314B1/pl unknown
- 1994-07-02 SK SK1617-95A patent/SK283263B6/sk not_active IP Right Cessation
- 1994-07-02 DK DK94924713T patent/DK0706513T3/da active
- 1994-07-02 JP JP07503287A patent/JP3093271B2/ja not_active Expired - Lifetime
- 1994-07-02 ES ES94924713T patent/ES2176252T3/es not_active Expired - Lifetime
- 1994-07-02 CN CN94192659A patent/CN1046939C/zh not_active Expired - Lifetime
- 1994-07-02 US US08/564,322 patent/US5712298A/en not_active Expired - Lifetime
- 1994-07-02 WO PCT/EP1994/002169 patent/WO1995001338A1/de active IP Right Grant
- 1994-07-02 PT PT94924713T patent/PT706513E/pt unknown
- 1994-07-02 HU HU9503541A patent/HU220041B/hu active Protection Beyond IP Right Term
- 1994-07-02 SG SG9605206-3A patent/SG143011A1/en unknown
- 1994-07-02 CA CA002165192A patent/CA2165192C/en not_active Expired - Lifetime
- 1994-07-02 AT AT94924713T patent/ATE217612T1/de active
- 1994-07-02 NZ NZ271316A patent/NZ271316A/en not_active IP Right Cessation
-
1995
- 1995-12-21 NO NO19955211A patent/NO305598B1/no not_active IP Right Cessation
- 1995-12-29 FI FI956333A patent/FI112864B/fi not_active IP Right Cessation
-
1998
- 1998-12-08 HK HK98112932A patent/HK1011690A1/xx not_active IP Right Cessation
-
2003
- 2003-05-13 LV LVP-03-48A patent/LV13074B/lv unknown
- 2003-11-11 CY CY0300082A patent/CY2389B1/xx unknown
-
2010
- 2010-07-21 LU LU91709C patent/LU91709I2/fr unknown
- 2010-09-29 CY CY2010015C patent/CY2010015I2/el unknown
- 2010-09-30 NO NO2010018C patent/NO2010018I1/no unknown
- 2010-12-06 FR FR10C0052C patent/FR10C0052I2/fr active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HU220041B (hu) | Fluor-alkoxi-helyettesített benzamidszármazékok, eljárás előállításukra és ezeket a vegyületeket tartalmazó gyógyászati készítmények | |
JP4146894B2 (ja) | ジヒドロベンゾフラン | |
US5587383A (en) | Imidazopyridine derivatives and their use | |
US5902824A (en) | Phenyldihydrobenzofuranes | |
US20050065188A1 (en) | Aryl or heteroaryl amide compounds | |
WO1995028387A1 (fr) | Compose benzamide et utilisation medicale dudit compose | |
JP2005170924A (ja) | Nos阻害剤として有用な6−フェニルピリジル−2−アミン誘導体 | |
CA2335104C (en) | Arylalkanoylpyridazines | |
KR100812586B1 (ko) | P38 키나아제 저해제로서 유용한 퀴나졸린 화합물 | |
JPS62149662A (ja) | N−含有複素環化合物 | |
SK1897A3 (en) | Benzamidines, its preparation, pharmaceutical composition containing them and their use | |
JPH04182467A (ja) | ジアリールメトキシピペリジン誘導体 | |
JP4248245B2 (ja) | 6−フェニルベンゾナフチリジン | |
JPH01313469A (ja) | キナゾリン、その製法及びこれを含有する抗腫瘍作用を有する製薬学的組成物 | |
KR101880965B1 (ko) | 피페라지닐 피리미딘 유도체, 그의 제조방법 및 용도 | |
US8552035B2 (en) | Phenanthrenone compounds, compositions and methods | |
JPH0324064A (ja) | 1―フェニル―1,4―ジヒドロ―3―アミノ―4―オキソピリダジン誘導体、その製造法および治療用途 | |
CN117658868A (zh) | 一种苯甲酰胺类衍生物及其制备方法和用途 | |
TW200300083A (en) | Benzamide, heteroarylamide and reverse amides | |
JPH03261765A (ja) | ピリドン誘導体及びその製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HPC4 | Succession in title of patentee |
Owner name: ALTANA PHARMA AG, DE |
|
AA1S | Information on application for a supplementary protection certificate |
Free format text: PRODUCT NAME: ROFLUMILAST, ROFLUMILAST OXIDE AND THEIR SALTS; REG. NO/DATE: EU/1/10/636/001-EU/1/10/636/003 20100705 Spc suppl protection certif: S1000016 Filing date: 20100916 Expiry date: 20140702 |
|
FG4S | Grant of supplementary protection certificate |
Free format text: PRODUCT NAME: ROFLUMILAST, ROFLUMILAST OXIDE AND THEIR SALTS; REG. NO/DATE: EU/1/10/636/001-EU/1/10/636/003 20100705 Spc suppl protection certif: S1000016 Filing date: 20100916 Expiry date: 20140702 Extension date: 20190702 |
|
HC9A | Change of name, address |
Owner name: TAKEDA GMBH, DE Free format text: FORMER OWNER(S): ALTANA PHARMA AG, DE; BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH., DE; NYCOMED GMBH,DE |